Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for CALIDI BIOTHERPUTICS WTS (CLDWW) aggregates regulatory disclosures connected to the underlying issuer, Calidi Biotherapeutics, Inc. These filings, accessed from the EDGAR system, provide structured information about the company whose common stock trades on NYSE American under the symbol CLDI and to which the CLDWW warrants are linked.
Calidi Biotherapeutics, Inc. uses Form 8-K to report a range of material events. Under Item 2.02 (Results of Operations and Financial Condition), the company has furnished a press release announcing financial results for a third quarter and discussing recent corporate developments. The filing clarifies that this information is furnished, not filed, for purposes of Section 18 of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings without specific reference.
Several 8-Ks provide Regulation FD disclosures under Item 7.01. These include the presentation of new data on the first therapeutic candidate from the RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer Annual Meeting, with a webinar presentation and poster furnished as exhibits, as well as an updated corporate presentation made available and a press release announcing a scientific advisory board focused on the RedTail platform and CLD-401.
Other filings detail material definitive agreements and corporate actions. Under Item 1.01, the company reports a Stock Repurchase Agreement and a Material Purchase Agreement with its then majority-owned subsidiary, Nova Cell, Inc., resulting in the sale and transfer of Nova Cell shares and certain materials, and Nova Cell no longer being a subsidiary. The Material Purchase Agreement amends and supersedes an earlier Intellectual Property Assignment Agreement, which is terminated as described under Item 1.02. Another 8-K, under Items 1.01 and 5.02, discusses the elimination of the Chief Legal Officer position, the termination of an employment agreement, and the execution of a General Release of Claims and Separation Agreement and a consulting agreement, in connection with cost-reduction and operating-efficiency initiatives.
On this page, AI-powered tools can help summarize and explain such 8-K disclosures, highlighting key items like financial result announcements, Regulation FD communications, asset and subsidiary transactions, and changes in executive roles. This allows users researching CLDWW and the underlying CLDI common stock to quickly understand the substance of Calidi Biotherapeutics, Inc.’s filings without reading every line of each document.
Calidi Biotherapeutics, Inc. is eliminating the Chief Legal Officer role as part of cost‑reduction and operating‑efficiency initiatives, leading to the termination of Chief Legal Officer Wendy Pizarro Campbell’s employment agreement effective October 17, 2025. The company states the decision is not due to any disagreement with her on operations, policies, or practices.
After a seven‑business‑day revocation period following a September 17, 2025 General Release of Claims and Separation Agreement, Ms. Campbell is entitled to a bonus of $85,000 if a corporate spin‑off, out‑licensing, or similar transaction relating to Nova Cell is successfully completed before October 31, 2025, plus $212,500 of severance pay over six months and six months of COBRA premiums. She will also provide services under a separate consulting agreement effective October 18, 2025 at $250 per hour, up to 20 hours per month for an initial six‑month term. The Board appointed Chief Financial Officer Andrew Jackson as Corporate Secretary as of the effective date.